Nexthera Capital LP acquired a new position in TG Therapeutics Inc (NASDAQ:TGTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $246,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Teacher Retirement System of Texas acquired a new stake in shares of TG Therapeutics in the 4th quarter worth about $151,000. Ellington Management Group LLC purchased a new stake in TG Therapeutics in the 4th quarter valued at about $203,000. First Mercantile Trust Co. increased its stake in TG Therapeutics by 28.6% in the 4th quarter. First Mercantile Trust Co. now owns 26,701 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 5,938 shares during the last quarter. Voya Investment Management LLC increased its stake in shares of TG Therapeutics by 40.2% during the 2nd quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after purchasing an additional 6,463 shares during the last quarter. Finally, CIBC World Markets Inc. purchased a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $250,000. 50.63% of the stock is currently owned by institutional investors and hedge funds.
In related news, CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the transaction, the chief financial officer now owns 517,464 shares in the company, valued at approximately $4,398,444. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 16.70% of the stock is owned by company insiders.
TGTX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research note on Monday, December 11th. B. Riley began coverage on shares of TG Therapeutics in a report on Friday, December 1st. They issued a “buy” rating and a $21.50 price objective for the company. Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a report on Tuesday, December 12th. BidaskClub downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, Zacks Investment Research downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. TG Therapeutics presently has an average rating of “Buy” and an average target price of $24.60.
TG Therapeutics Inc (TGTX) traded up $0.05 during trading on Tuesday, hitting $16.00. 418,333 shares of the stock traded hands, compared to its average volume of 1,663,936. The stock has a market cap of $1,224.39, a PE ratio of -8.34 and a beta of 1.40. TG Therapeutics Inc has a 12-month low of $7.25 and a 12-month high of $17.35.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, hitting analysts’ consensus estimates of ($0.46). The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 145.58%. equities research analysts forecast that TG Therapeutics Inc will post -1.68 earnings per share for the current fiscal year.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.